Corporate News

Key highlights

Filter

Period

Filter by

recent search

Showing: 1 – 05 of 16 Corporate News

Ipsen to acquire exclusive rights to investigational ERK inhibitor as part of its existing research collaboration with AGV Discovery
Ipsen to acquire exclusive rights to investigational ERK inhibitor as part of its existing research collaboration with AGV Discovery

PARIS, & MONTPELLIER, FRANCE, 1st August 2022 – Ipsen (Euronext: IPN; ADR: IPSEY) and AGV Discovery today announced that Ipsen has exercised its option to acquire exclusive worldwide rights to an investigational ERK inhibitor, discovered by AGV Discovery.


Ipsen to acquire Epizyme, expanding its portfolio in oncology
Ipsen to acquire Epizyme, expanding its portfolio in oncology

PARIS, FRANCE & CAMBRIDGE, MASSACHUSETTS, 27 June 2022 – Ipsen (Euronext: IPN; ADR: IPSEY) and Epizyme (Nasdaq: EPZM) today announced that they have entered into a definitive merger agreement under which Ipsen will acquire Epizyme. The transaction was unanimously approved by…


Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor, a Phase III asset evaluated in Primary Biliary Cholangitis, as part of a long-term global partnership

Ipsen and Exicure enter into exclusive collaboration targeting rare neurodegenerative disorders

Ipsen strengthens its pre-clinical Oncology pipeline with an exclusive worldwide-collaboration with BAKX Therapeutics Inc. for BKX-001, targeting the apoptosis pathway

1 2 3 4

Your dedicated contacts